Home›Trial›NCT05599191
🔬NCT05599191Phase 3ACTIVE NOT RECRUITING

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

Study Summary

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Conditions
CoughRefractory Chronic Cough
Interventions / Drugs
BLU-5937Placebo
View on ClinicalTrials.gov ↗
Sponsor
BLU
BELLUS Health
Chronic Cough
C61/100
Study Details
Enrollment825 participants
Primary Completion—
Lead SponsorBellus Health Inc. - a GSK company
Data Retrieved2026-04-11 04:07:59.947174+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.